Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center

Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes the switching process at a National Cancer Institute...

Descripción completa

Detalles Bibliográficos
Autores principales: Piezzo, Michela, D’Aniello, Roberta, Avallone, Ilaria, Barba, Bruno, Cianniello, Daniela, Cocco, Stefania, D’Avino, Antonio, Di Gioia, Germira, Di Lauro, Vincenzo, Fusco, Giuseppina, Piscitelli, Raffaele, von Arx, Claudia, De Laurentiis, Michelino, Maiolino, Piera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151152/
https://www.ncbi.nlm.nih.gov/pubmed/34068626
http://dx.doi.org/10.3390/pharmaceutics13050684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151152/
https://www.ncbi.nlm.nih.gov/pubmed/34068626
http://dx.doi.org/10.3390/pharmaceutics13050684

Ejemplares similares